| Contributors | |
| Preface | |
| New Insights Into the Epidemiology and Natural History of Benign Prostatic Hyperplasia | 3 |
| Anatomy of the Prostate: Insight Into Benign Prostatic Hyperplasia Anatomy and Pathogenesis | 21 |
| The Pathogenesis of BPH: Role of Hormones | 33 |
| The Role of Growth Factors in the Pathogenesis of BPH | 43 |
| Benign Prostatic Hyperplasia: Morphometric Studies in Relation to the Hormone Sensitivity of Stromal Tissue | 51 |
| Human Papilloma Virus Type 18 DNA Immortalized Cell Lines From the Human Prostate Epithelium | 67 |
| The Assessment of Patient Complaints | 73 |
| Signs and Symptoms of Benign Prostatic Hyperplasia in Men Screened for Prostatic Carcinoma | 97 |
| A Critique of Scoring Systems | 109 |
| Correlation Between Urinary Flow Rate, Voided Volume, and Patient Age in a Community-Based Population | 125 |
| The Principles and Clinical Application of Advanced Urodynamic Analysis for BPH | 141 |
| Urodynamic Assessment of Obstruction Prior to and After Surgery or Medical Treatment for BPH | 157 |
| Urodynamic Assessment of Voiding Dysfunction in Patients With BPH. Is It Necessary? Panel Discussion | 167 |
| The Assessment of Medical Treatment of Benign Prostatic Hyperplasia (BPH) | 175 |
| Medical Treatment of Benign Prostatic Hyperplasia: The Effect of Surgical or Medical Castration | 191 |
| Benign Prostatic Hyperplasia: Dihydrotestosterone and 5 Alpha-Reductase Inhibition Therapy | 197 |
| Clinical Results With Finasteride | 205 |
| The Function and the Role of Aromatase Inhibitors in the Treatment of BPH | 209 |
| Endocrine Therapies for BPH: Scientific Rationale, Clinical Results, and Patient Selection | 231 |
| The Pathophysiology of Clinical BPH | 253 |
| Effects of Obstruction on Bladder Contractile Proteins | 263 |
| Prostatic Alpha Adrenoceptors | 271 |
| The Role of Alpha Blockers in BPH | 279 |
| Clinical Results With [alpha]-Blockers in Patients With Symptomatic Benign Prostatic Hyperplasia | 285 |
| Analysis of Watchful Waiting Studies | 291 |
| Medical Management of Benign Prostatic Hyperplasia Other Than With Hormones or Alpha Blockers | 303 |
| The Role of the General Practitioner in the Diagnosis and Treatment of Benign Prostatic Hyperplasia (BPH) | 313 |
| BPH: When to Rule out Carcinoma of the Prostate | 333 |
| Benign Prostatic Hyperplasia: The Incidence of Prostatectomy Within and Without Europe | 345 |
| The Indications for Surgical Treatment of BPH | 357 |
| Selection of the Surgical Procedure for Management of Benign Prostatic Hyperplasia | 369 |
| The Morbidity and Mortality of BPH Surgery | 385 |
| Fluid Absorption and Endotoxinemia During Transurethral Prostatic Resection | 391 |
| Video-TUR: Raising the Golden Standard | 401 |
| Economics of BPH: Measuring the Intangible Costs | 409 |
| Some Socio-Economic Issues Surrounding Prostatectomy: The US Experience | 419 |
| The Rational Basis for Thermotherapy of BPH | 429 |
| Hyperthermia: A Randomized Prospective Study Applying Hyperthermia or a Sham Procedure in Obstructive Benign Hyperplasia of the Prostate | 439 |
| The Efficacy of Microwave Induced Hyperthermia in the Treatment of BPH: The Paris Public Hospitals' Experience | |
| Transurethral Microwave Thermotherapy Versus Transurethral Resection for BPH | 455 |
| High Intensity Focused Ultrasound Treatment of Human BPH | 463 |
| Thermal Ablation of BPH With Transrectal High-Intensity Focused Ultrasound | 473 |
| Transurethral Needle Ablation (TUNA): Histopathological, Radiological, and Clinical Studies of a New Office Procedure for Treatment of Benign Prostatic Hyperplasia | 479 |
| Thermotherapy and Hyperthermia Workshop | 487 |
| Laser Dosimetry Studies in a Canine Prostate Model | 501 |
| Optimization of Laser Prostatectomy | 511 |
| Interstitial Laser Coagulation of the Prostate: Experiences in the Treatment of Benign Prostatic Hyperplasia | 521 |
| Transurethral Ultrasound Guided Laser Induced Prostatectomy (TULIP): U.S. Cooperative Study and University of Bochum Results | 529 |
| Laser Treatment of Benign Prostatic Hyperplasia (BPH) Workshop | 535 |
| Other Non-Medical Treatments: Balloons and Stents | 547 |
| The UroLume Endoprosthesis: A Summary of the European and North American Experience | 561 |
| Alternative Surgical Treatments for Obstructive BPH: Balloons and Stents | 577 |
| Retreatment Rate After Surgical and Non-Surgical Treatments | 597 |
| International Consultation on Benign Prostatic Hyperplasia | 617 |
| Index | 625 |
loading...